COVID-19 Drives Increased Pharma-Bio Diagnostics Facility Spending
COVID-19 Drives Increased Pharma-Bio Diagnostics Facility Spending
Attachment: dia
SUGAR LAND--April 12, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--The diagnostics cohort of the Pharmaceutical-Biotech Industry, namely in vitro diagnostics (IVD) tests, are considered medical devices. Diagnostic products may be reagents, techniques, instruments, or a combination of these used in vitro for the examination of specimens such as blood, urine or tissue with the goal of obtaining a diagnosis from assays in a controlled environment outside a living organism.
Industrial Info's Pharma/Bio group is currently tracking 93 active U.S. and Canada diagnostics substances projects with a total investment value of $1.56 billion.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects